1. Differences in antimicrobial susceptibility testing complicating management of IMP carbapenemase-producing Enterobacterales infection
- Author
-
Séamus Fanning, O. O'Donoghue, João Anes, Daniel Hurley, S. Nguyen, Kirsten Schaffer, and Caitríona Hickey
- Subjects
Microbiology (medical) ,Carbapenem ,Immunology ,Carbapenemase-producing Enterobacterales ,Tigecycline ,Microbiology ,Meropenem ,beta-Lactamases ,chemistry.chemical_compound ,Bacterial Proteins ,polycyclic compounds ,medicine ,Humans ,Immunology and Allergy ,Antimicrobial susceptibility testing ,Blood culture ,Etest ,medicine.diagnostic_test ,business.industry ,Broth microdilution ,CPE ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,QR1-502 ,Anti-Bacterial Agents ,IMP carbapenemase ,chemistry ,Amikacin ,bacteria ,business ,Ertapenem ,medicine.drug - Abstract
Objectives IMP-type carbapenemases are rarely detected in Europe and limited information is available to guide the treatment of infections caused by carbapenemase-producing Enterobacterales (CPE) producing these carbapenemases. Accurate antimicrobial susceptibility testing (AST) results are essential for optimal antibiotic management. Here we report discrepancies in AST of IMP-producing Enterobacterales (IMP-CPE) complicating the management of severe sepsis. Methods Antimicrobial susceptibilities were analysed by in-house VITEK® 2, Etest and broth microdilution (BMD). Carbapenemase-encoding genes were detected by PCR. Whole-genome sequencing (WGS) was performed using an Illumina MiSeq platform. Results Minimum inhibitory concentrations (MICs) determined by VITEK® 2 for Enterobacter hormaechei and Klebsiella oxytoca blood culture isolates were ≥16 mg/L for meropenem and ≤0.5 mg/L for ertapenem. In contrast, Etest analysis and BMD returned MICs of 2 mg/L and 1 mg/L, respectively. Both isolates tested positive for IMP carbapenemase-encoding genes by PCR. WGS revealed that both isolates carried the same blaIMP-4 gene. Based on VITEK® 2 susceptibilities, initial treatment was with tigecycline and amikacin. After subsequent deterioration, the patient was successfully treated with ertapenem and amikacin. Conclusion This case highlights that automated AST by VITEK® 2 can over-report meropenem resistance for IMP carbapenemase-producers compared with Etest and BMD. Clinicians need to be cautious deciding against carbapenem treatment based on VITEK® 2 susceptibility testing results for IMP-positive Enterobacterales. Tigecycline was inferior to carbapenem treatment for pyelonephritis caused by isolates expressing IMP carbapenemases, however specific evidence guiding the treatment of these infections is lacking.
- Published
- 2021